Skip to main content
Equibles

Vojislav Vukovic

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Vojislav Vukovic

Rein Therapeutics, Inc. reported in an 8-K filed July 8, 2022 that Vojislav Vukovic was terminated as Senior Vice President, Chief Medical Officer, effective July 8, 2022. The proxy statement of Rein Therapeutics, Inc. reports total compensation of $545,703 for Vojislav Vukovic in fiscal 2022, including a base salary of $248,566. Disclosed compensation is on record for 5 fiscal years.

“On July 8, 2022, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Separation and Release of Claims Agreement with Vojislav Vukovic, M.D., Ph.D. (the “Separation Agreement”), which provides for Dr. Vukovic’s separation of employment as Senior Vice President, Chief Medical Officer of the Company, effective July 8, 2022 (the “Separation Date”).”
Rein Therapeutics, Inc. Form 8-K, filed July 8, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Rein Therapeutics, Inc. (RNTX) $248,566 $545,703
2021 Rein Therapeutics, Inc. (RNTX) $423,225 $962,386
2020 Rein Therapeutics, Inc. (RNTX) $405,000 $778,930
2019 Rein Therapeutics, Inc. (RNTX) $405,000 $650,843
2018 Rein Therapeutics, Inc. (RNTX) $64,614 $436,965

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.